Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial

Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial

A pivotal multicenter randomized trial demonstrates that oral Realgar-Indigo naturalis formula (RIF) combined with ATRA is non-inferior to arsenic trioxide (ATO) plus ATRA, providing a simplified consolidation regimen for non-high-risk APL with excellent 2-year disease-free survival and manageable toxicity.
Comparative Effectiveness of Cupping and Scraping Therapy Versus NSAIDs for Chronic Nonspecific Low-Back Pain: Insights from a Multicenter Randomized Trial

Comparative Effectiveness of Cupping and Scraping Therapy Versus NSAIDs for Chronic Nonspecific Low-Back Pain: Insights from a Multicenter Randomized Trial

A recent multicenter randomized trial demonstrates superior short-term efficacy of cupping and scraping therapy with medicated balm over NSAIDs with capsaicin plasters in reducing pain and improving quality of life for chronic nonspecific low-back pain.
Therapist-Guided Internet CBT Cuts Bulimia Episodes: A Japanese Randomized Trial with Promising Clinical Implications

Therapist-Guided Internet CBT Cuts Bulimia Episodes: A Japanese Randomized Trial with Promising Clinical Implications

A multicenter randomized trial in Japan found that a 12-week therapist-guided internet-based CBT program significantly reduced weekly bingeing and compensatory episodes in women with bulimia nervosa versus usual care (adjusted mean difference 9.84 episodes; Cohen d 0.73).

Ketogenic Diet vs Further Antiseizure Medication in Infants with Drug-Resistant Epilepsy: What the KIWE Trial Adds to Clinical Practice

The KIWE randomised trial (Lancet Neurol 2023) found no superiority of a classic ketogenic diet over an additional antiseizure medication for seizure frequency in infants (1–24 months) with drug‑resistant epilepsy; tolerability and safety profiles were similar, supporting the diet as a viable treatment option.